Department of Rheumatology, Western Health, Victoria, Australia.
Clin Rheumatol. 2020 Feb;39(2):613-614. doi: 10.1007/s10067-019-04833-6. Epub 2019 Nov 28.
The aim of RA treatment is to achieve reduction of disease activity and prevent joint damage and disability. Baricitinib is a synthetic small molecule which targets the JAK/STAT pathway which is implicated in the inflammatory response in RA. Baricitinib selectively targets JAK1 and JAK2 and has been shown to have efficacy in treating patients with RA. Common adverse effects reported during baricitinib therapy includes infection, asymptomatic changes in laboratory parameters including changes in neutrophil, lymphocyte, platelet counts, alanine aminotransferase, cholesterol, creatinine and creatine kinase (CK). We report the first two documented cases in Australia of baricitinib-induced symptomatic elevation of CK.
RA 治疗的目的是实现疾病活动的减少，并预防关节损伤和残疾。巴利昔替尼是一种合成的小分子，其作用靶点是 JAK/STAT 通路，该通路与 RA 中的炎症反应有关。巴利昔替尼选择性地靶向 JAK1 和 JAK2，已被证明在治疗 RA 患者方面具有疗效。巴利昔替尼治疗期间报告的常见不良反应包括感染、实验室参数的无症状变化，包括中性粒细胞、淋巴细胞、血小板计数、丙氨酸氨基转移酶、胆固醇、肌酐和肌酸激酶 (CK) 的变化。我们报告了澳大利亚首例两例有症状的巴利昔替尼诱导的 CK 升高的病例。
